GC
NRIX icon

Guggenheim Capital’s Nurix Therapeutics NRIX Stock Holding History

Guggenheim Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,630
Closed -$250K – 2166
2021
Q4 		$250K Buy
8,630
+1,928
+29% +$58.4K ﹤0.01% 1954
2021
Q3 		$201K Buy
+6,702
New +$207K ﹤0.01% 2069

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Guggenheim Capital's NRIX Position: Q1 2022 in Review

Guggenheim Capital sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 8,630 shares — an estimated $250K sold.

Guggenheim Capital first reported a position in NRIX in Q3 2021 and held it in 2 quarters. The position peaked at $250K in Q4 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • Guggenheim Capital reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Guggenheim Capital sold 8,630 Nurix Therapeutics shares in Q1 2022, an estimated $250K.
  • Guggenheim Capital first reported a position in Nurix Therapeutics in Q3 2021 and held it in 2 quarters.
  • Guggenheim Capital's Nurix Therapeutics position peaked at $250K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Guggenheim Capital's 13F filing for Q1 2022, filed 16 May 2022.